Pediatric low-grade glioma specialists examine recent therapeutic advancements and their practical implications, presenting two real-world cases to demonstrate the integration of new data into clinical decision-making.
August 23rd 2024
The panel reviews ongoing clinical trials aimed at expanding treatment options for progressive pediatric low-grade gliomas (pLGG), with a specific focus on the PNOC021, PBTC-055, and NF111 studies, discussing their objectives, design features, and potential impact on future treatment strategies.
The panel examines a specific patient case, offering detailed insights into their decision-making process and treatment approaches for patients with pediatric low-grade gliomas (pLGG).
August 30th 2024
The panel presents alternative treatment options and key considerations for the discussed clinical scenario, elaborating on the factors that influence their decision-making process.
The key opinion leaders analyze a second clinical scenario, focusing on a patient with a BRAF V600E mutation in their pediatric low-grade glioma (pLGG).
September 6th 2024
The panel of pediatric low-grade glioma (pLGG) experts delves into the potential adverse events associated with targeted therapies, outlining common reactions and their severity, while also sharing their strategies and best practices for toxicity management.
The leaders in the pediatric low-grade glioma (pLGG) field offer their concluding insights and perspectives on the future of pLGG management.